What is on the differential diagnosis for Hyperphosphatemia and Hypophosphatemia?

Key differentials include Pseudohyperphosphatemia, Pseudohypophosphatemia, Tumor lysis syndrome, CKD-MBD, Refeeding syndrome, X-linked hypophosphatemic rickets, Oncogenic osteomalacia.

What are the high-yield PANCE pearls for Hyperphosphatemia and Hypophosphatemia?

Severe hypophosphatemia (<1.0 mg/dL) can cause acute respiratory failure from diaphragmatic weakness — always check phosphate in unexplained ventilator dependence. Watch for refeeding syndrome in anorexia, alcoholism, post-bariatric, and prolonged NPO patients — start nutrition slowly and pre-replete electrolytes. Calcium-containing binders can worsen vascular calcification — non-calcium binders (sevelamer, lanthanum, ferric citrate) are preferred in dialysis patients with vascular disease. IV ferric carboxymaltose is an underrecognized cause of hypophosphatemia, sometimes severe and prolonged. Hyperphosphatemia + hypocalcemia + hyperuricemia + hyperkalemia + AKI = tumor lysis syndrome until proven otherwise.

Renal/Urology · PANCE / PANRE

Hyperphosphatemia and Hypophosphatemia

Q: What is Hyperphosphatemia and Hypophosphatemia?

Disorders of phosphate homeostasis from CKD, vitamin D abnormalities, refeeding, or tumor lysis.

Written & clinically reviewed by Ryan Busch, PA-C · Updated July 2026 · Report an error

Disorders of phosphate homeostasis from CKD, vitamin D abnormalities, refeeding, or tumor lysis.

Also known as: hyperphosphatemia, hypophosphatemia, phosphate disorder, phosphorus disorder, refeeding syndrome

Overview

Hyperphosphatemia is serum phosphate >4.5 mg/dL in adults (>7 in young children). Hypophosphatemia is serum phosphate <2.5 mg/dL, with severe <1.0 mg/dL. Phosphate homeostasis is regulated by dietary intake, intestinal absorption (1,25-dihydroxyvitamin D dependent), renal excretion (PTH and FGF-23 dependent), and shifts between extracellular and intracellular compartments.

Epidemiology

Hyperphosphatemia is nearly universal in advanced CKD (eGFR <30) and end-stage renal disease. Hypophosphatemia occurs in ~5% of hospitalized patients and up to 30% of ICU patients, often from refeeding, sepsis, diabetic ketoacidosis recovery, or alcohol use disorder.

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Hyperphosphatemia and Hypophosphatemia outline — plus all 514 diagnoses, 5,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Start your 7-day free trial → Sign in

Free to start · No credit card · Cancel anytime

Risk factors

Hyperphosphatemia: CKD/ESKD (most common), tumor lysis syndrome, rhabdomyolysis, hypoparathyroidism, vitamin D toxicity, phosphate-containing bowel preps and laxatives, acidosis, hemolysis (artifactual)
Hypophosphatemia: refeeding syndrome (malnutrition, anorexia, alcoholism, post-bariatric), DKA recovery, respiratory alkalosis (intracellular shift), primary or secondary hyperparathyroidism, X-linked hypophosphatemic rickets, oncogenic osteomalacia (FGF-23–secreting tumor), Fanconi syndrome, IV iron (ferric carboxymaltose, iron isomaltoside), prolonged thiazide or loop diuretic use, vitamin D deficiency

Pathophysiology

Hyperphosphatemia: reduced renal excretion (low GFR) is the dominant mechanism in CKD; high turnover (tumor lysis, rhabdo) or transcellular shift (acidosis) contributes acutely. Chronic hyperphosphatemia drives FGF-23 release, secondary hyperparathyroidism, and CKD-MBD with vascular calcification. Hypophosphatemia: result of decreased intake, decreased absorption, transcellular shift (refeeding insulin surge, respiratory alkalosis), or increased renal loss (PTH, FGF-23 excess, Fanconi). Severe depletion impairs ATP, 2,3-DPG, and cellular function.

Clinical presentation

Symptoms

Hyperphosphatemia: often asymptomatic; pruritus, bone pain, soft-tissue calcification; symptoms of hypocalcemia (precipitation as calcium phosphate) — paresthesias, tetany, seizures
Hypophosphatemia (severe): muscle weakness, respiratory failure (diaphragmatic weakness), rhabdomyolysis, hemolysis, paresthesias, confusion, seizures, cardiac dysfunction

Signs / physical exam

Hyperphosphatemia: signs of associated hypocalcemia (Chvostek, Trousseau), calciphylaxis lesions in ESKD, evidence of vascular calcification
Hypophosphatemia: proximal muscle weakness, decreased respiratory effort, rhabdomyolysis (dark urine, CK elevation), congestive heart failure in severe deficit

Classic findings

Calciphylaxis (ischemic skin necrosis) in dialysis patients with chronically elevated calcium-phosphate product. Refeeding syndrome with severe hypophosphatemia within 72 h of nutrition initiation in a starved patient.

Differential diagnosis

Pseudohyperphosphatemia — Hemolysis, paraproteinemia, hyperbilirubinemia, liposomal amphotericin — repeat with proper sample handling
Pseudohypophosphatemia — Hyperbilirubinemia or mannitol interference in assay
Tumor lysis syndrome — Hyperphosphatemia + hyperuricemia + hyperkalemia + hypocalcemia after chemotherapy
CKD-MBD — Hyperphosphatemia + secondary hyperparathyroidism + low 1,25-vitamin D ± low calcium
Refeeding syndrome — Severe hypophosphatemia within 72 h of refeeding in a starved or alcoholic patient; also low K, Mg
X-linked hypophosphatemic rickets — FGF-23 excess, low phosphate, normal calcium, short stature, bowing of legs
Oncogenic osteomalacia — Adult with bone pain and severe hypophosphatemia; elevated FGF-23 from mesenchymal tumor

Diagnostic workup

Diagnostic criteria

Cutoffs vary slightly by lab. KDIGO CKD-MBD recommends keeping phosphate in the normal range in CKD patients on dialysis. Hypophosphatemia severity: mild 2.0-2.5, moderate 1.0-2.0, severe <1.0 mg/dL — treatment thresholds depend on severity and symptoms.

Labs

Serum phosphate (fasting; nonhemolyzed) — confirm with repeat sample
Calcium (total and ionized), albumin, magnesium, PTH, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D
BMP, eGFR, BUN/Cr
Urine phosphate (24-hour or fractional excretion of phosphate, FEPO4) to assess renal handling — high in renal wasting, low in intake/shift causes
If unclear etiology: FGF-23 level (elevated in X-linked hypophosphatemia, oncogenic osteomalacia, CKD-MBD), urine glucose/amino acids (Fanconi screen)
CBC, CK, LDH, uric acid (tumor lysis evaluation if relevant)

Imaging

DEXA scan if chronic phosphate disorder
Plain films/MRI for fractures, looser zones (osteomalacia)
68Ga-DOTATATE PET or octreotide scan for suspected FGF-23–secreting tumor

Diagnostic algorithm

Disorder	Major causes	Hallmark labs	Therapy
Hyperphosphatemia	CKD, tumor lysis, rhabdomyolysis, hypoparathyroidism, phosphate enemas	Low Ca, high PTH (CKD-MBD), high uric acid (TLS)	Dietary restriction, binders (sevelamer, lanthanum, calcium acetate), dialysis
Hypophosphatemia (moderate)	Refeeding, DKA recovery, alcoholism, hyperparathyroidism, vit D deficiency	Variable Ca; low Mg often coexists	Oral phosphate (K-Phos, Phos-Nak), milk
Hypophosphatemia (severe <1.0)	Refeeding, severe DKA, sepsis, IV iron, oncogenic osteomalacia	Respiratory failure, rhabdomyolysis	IV potassium or sodium phosphate; monitor Ca

Phosphate disorder summary — major etiologies and management.

Treatment

First-line

Hyperphosphatemia (CKD/ESKD): dietary phosphate restriction (~800-1000 mg/day; emphasize avoidance of phosphate additives in processed foods)
Phosphate binders with meals — calcium-based (calcium acetate, calcium carbonate) or non-calcium (sevelamer carbonate, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide)
Optimize dialysis (longer/more frequent sessions reduce phosphate effectively)
Hypophosphatemia (mild-moderate, asymptomatic): oral repletion — sodium or potassium phosphate (Phos-Nak, K-Phos Neutral); milk and dairy are practical sources
Hypophosphatemia (severe or symptomatic): IV phosphate — sodium phosphate or potassium phosphate; max 0.08-0.16 mmol/kg over 6 hours; monitor calcium (avoid precipitation)

Tumor lysis syndrome

Aggressive IV fluids (isotonic saline 2-3 L/m²/day)
Rasburicase for hyperuricemia
Phosphate binders, dialysis if severe
Avoid IV calcium unless symptomatic — risk of calcium phosphate precipitation

Refeeding syndrome

Start nutrition at 25-50% of goal and advance over 5-7 days
Replete phosphate, potassium, magnesium, and thiamine BEFORE and during refeeding
Daily electrolyte monitoring during first week

X-linked hypophosphatemic rickets / oncogenic osteomalacia

Burosumab (anti-FGF-23 monoclonal antibody) — first-line per Endocrine Society 2020
Phosphate and calcitriol supplementation as adjunct or alternative
Tumor resection for oncogenic osteomalacia when localizable

Severe CKD-MBD with elevated PTH

Calcimimetic (cinacalcet, etelcalcetide) to lower PTH and indirectly phosphate
Active vitamin D analogs (calcitriol, paricalcitol, doxercalciferol) with caution — can raise phosphate
Parathyroidectomy for refractory tertiary hyperparathyroidism

Second-line / adjunct

Acetazolamide (rare, for proximal tubular acidosis with hypophosphatemia)
Mineral and bone disorder team consultation
Tenapanor — intestinal phosphate absorption inhibitor in dialysis hyperphosphatemia

Complications

Hyperphosphatemia: vascular and soft-tissue calcification, calciphylaxis, secondary/tertiary hyperparathyroidism, renal osteodystrophy, increased cardiovascular mortality in CKD
Hypophosphatemia: respiratory failure (diaphragmatic weakness), rhabdomyolysis, hemolysis, cardiac dysfunction, encephalopathy, osteomalacia/rickets, fragility fractures

PANCE pearls

Severe hypophosphatemia (<1.0 mg/dL) can cause acute respiratory failure from diaphragmatic weakness — always check phosphate in unexplained ventilator dependence.
Watch for refeeding syndrome in anorexia, alcoholism, post-bariatric, and prolonged NPO patients — start nutrition slowly and pre-replete electrolytes.
Calcium-containing binders can worsen vascular calcification — non-calcium binders (sevelamer, lanthanum, ferric citrate) are preferred in dialysis patients with vascular disease.
IV ferric carboxymaltose is an underrecognized cause of hypophosphatemia, sometimes severe and prolonged.
Hyperphosphatemia + hypocalcemia + hyperuricemia + hyperkalemia + AKI = tumor lysis syndrome until proven otherwise.

References

KDIGO CKD-MBD 2017 — KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-Mineral and Bone Disorder (Kidney Int Suppl 2017;7:1-59)
Endocrine Society 2020 — Clinical Practice Guideline on X-linked Hypophosphatemia (Carpenter TO et al., JCEM 2020;105:1009-1023)
Refeeding — Friedli N et al. Refeeding syndrome: revisiting the etiology and management (Nutrition 2017;35:151-160)
Tumor lysis — Coiffier B et al. Guidelines for the management of tumor lysis syndrome in adults and children with malignancies (JCO 2008;26:2767-2778)

Practice Renal/Urology questions on FirstPassPA

Turn this outline into retention. 5,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.